Synthetic polymers against fungal infections

Combined with antifungal drugs, synthetic polymers are particularly effective against Candida albicans. This was discovered by a German-Australian research team, who also elucidated the mechanism of action behind this.

The researchers presented their findings in Nature Communications. The international collaboration came about by chance through an unplanned research stay that initiated the study at the Leibniz-HKI in Jena.

Every year, more than two million people are affected by invasive fungal infections, which are often caused by Candida species and are associated with high mortality rates. The development of new therapies is progressing very slowly. Demand is increasing, however, especially as drug resistance is becoming more and more common.

An interdisciplinary research team led by Dr. Sascha Brunke from the Leibniz Institute for Natural Product Research and Infection Biology - Hans Knöll Institute (Leibniz-HKI) has now investigated the mode of action and therapeutic potential of synthetic polymers. These long-chain chemical compounds mimic naturally occurring peptides and inhibit the growth of microorganisms. The exact mechanism of action was previously unclear. However, the mystery has now been solved - all thanks to the coronavirus pandemic.

From Australia to Jena

Doctoral researcher Sebastian Schäfer, who was working on the design of antifungal polymers in chemical engineering at the University of New South Wales (UNSW), was in Germany when Australia closed its borders due to the pandemic. This prevented Schäfer from returning to UNSW.

But the biotechnologist made a virtue of necessity and temporarily moved his research to the Leibniz-HKI in Jena, where he added a chemical facet to the Department of Microbial Pathogenicity Mechanisms and turned his attention to pathogenic fungi. This not only led to new research approaches, but also to a very successful collaboration between natural product researchers and infection biologists from Germany and Australia.

New synthetic polymers with strong efficacy

The unexpectedly formed team developed several synthetic polymers from the polyacrylamide family that showed strong efficacy against Candida albicans, even against resistant strains. In particular, the polymer called LH, in combination with the drug caspofungin, was extremely effective against the fungus and significantly improved the survival rate of infected moth larvae in laboratory tests.

Sweeping blow against fungal cells

In the study, the team also uncovered the exact mode of action of the compounds for the first time. "The synthetic polymers attack the fungal cells in a number of different ways at the same time. They also use new target structures, which is why they are so effective. This is where they differ from conventional antifungals, which only work in one way," reports Raghav Vij, who is one of the authors of the study alongside Sebastian Schäfer.

The compounds caused stress in the fungal cell and weakened it by hindering glycosylation on the cell surface. In this chemical process, sugar chains are bound to proteins, which is important for the stability and function of the cells. The polymers also damaged the walls and membranes of the fungal cells, causing them to die. In addition, the polymers supported immune cells in the destruction of fungal cells, as was discovered in interaction tests.

Hope for resistant fungi

"It was also remarkable that LH together with antifungal agents did not lead to the development of resistance in C. albicans in the laboratory. This indicates that such combination therapies are not only more effective, but also more sustainable than previous therapies and can therefore lead to better treatment success," explains Vij. Another advantage: "The production of synthetic polymers is relatively inexpensive. In addition, they are stable and storable compared to conventional active compounds. In low-income countries in particular, they could therefore make a significant contribution to public health," summarizes Sascha Brunke.

However, more research is still needed before this is achieved. "So far, the polymers have only been tested in insect models. Whether humans also tolerate the new therapy must first be investigated in detail," Brunke points out. There is also still a need to optimize the structure of the polymers developed. "We don't yet know exactly which molecular components of the polymers affect which parts of the fungus. The target molecule is still missing, so to speak," says Vij. Moreover, it must be investigated whether the polymers have any harmful effects on humans or the environment. Despite everything, the research results already point in a positive direction and give hope for effective new therapeutic options.

The study was carried out as part of the Cluster of Excellence "Balance of the Microverse" and was funded by the German Research Foundation (DFG) and the Federal Ministry of Education and Research (BMBF), among others.

» Original publication

Source: Leibniz Institute for Natural Product Research and Infection Biology - Hans Knöll Institute (HKI)